CLINUVEL PHARMACEUTICALS LIMITED

3.44%

$9.83

Market Cap $492.7M

Healthcare Biotechnology

Clinuvel Pharmaceuticals Limited is an Australia-based global specialty pharmaceutical... Clinuvel Pharmaceuticals Limited is an Australia-based global specialty pharmaceutical company. The Company is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The Company’s pharmaceuticals product development includes PRENUMBRA and NEURACTHEL. Its PhotoCosmetics product development includes CYACELLE and DNA Repair Assist and Melanogenesis. PRENUMBRA is a formulation of afamelanotide designed to provide a flexible dose in identified patient groups. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH).More

ASX:AFP

Could this ASX stock become the next Pfizer? A look at AFT Pharmaceuticals (ASX:AFP). With biotech stocks broadly having a strong run in 2025, and with more of the year ahead, investors are still looking for stocks in the sector with room to run.

Latest Threads

Tag

Subject

CUV

Disc Medicine - Best comparison stock to Clinuvel

2 3 4

14/06/25

228

103K

14/06/25

Last post Silverchair

228

103K

CUV

Ann: CLINUVEL management update

13/06/25

3.5K

13/06/25

Last post minutesoup

3.5K

CUV

Clinuvel shares dip, even as CEO comes back from temp leave

13/06/25

304

13/06/25

Last post ASX Insights

304

CUV

Ann: SCENESSE successfully administered to paediatric EPP patient

13/06/25

1.2K

13/06/25

Last post DjohnR

1.2K

CUV

REPORT JUST DROPPED - Check this out!

12/06/25

11K

12/06/25

Last post Silverchair

11K

CUV

Did PW quit?

12/06/25

567

12/06/25

Last post LJSM

567

CUV

2025 YTD - Things are going well

11/06/25

5.9K

11/06/25

Last post Silverchair

5.9K

CUV

Ann: Notification of buy-back - CUV

06/06/25

9.9K

06/06/25

Last post ChrizzlyAdams

9.9K

See All Discussions

Timeline

CLINUVEL management update
13 Jun 09:35	Share

SCENESSE successfully administered to paediatric EPP patient
13 Jun 08:58	Share

SCENESSE in Vitiligo - A Global Update
04 Jun 10:07	Share

SCENESSE EPP data featured at EADV Symposium
22 May 08:57	Share

Ceasing to be a substantial holder
09 May 08:24	Share

CUV recruits 200 patients in Phase III vitiligo trial CUV105
07 May 08:41	Share

Notification regarding unquoted securities - CUV
23 Apr 09:00	Share

Notification of cessation of securities - CUV
09 Apr 08:22	Share

Section 708A Cleansing Statement
07 Apr 08:55	Share

Application for quotation of securities - CUV
07 Apr 08:51	Share

Application for quotation of securities - CUV
07 Apr 08:49	Share

Change in substantial holding
01 Apr 19:43	Share

Notification of buy-back - CUV
27 Mar 09:04	Share

CLINUVEL renews share buy-back program
27 Mar 09:03	Share

Update - Notification of buy-back - CUV
27 Mar 08:58	Share

Positive preliminary results for PRENUMBRA Instant in stroke
26 Mar 09:15	Share

2025 American Academy of Dermatology Annual Meeting
24 Mar 09:19	Share

CLINUVEL management update
18 Mar 09:02	Share

CLINUVEL Unveils Vitiligo Program for AAD 2025
04 Mar 08:59	Share

CLINUVEL Investor Webinar
28 Feb 09:06	Share

Chair Letter to Shareholders
28 Feb 09:04	Share

Half Year Results Presentation
27 Feb 10:48	Share

Half Year Results Announcement
27 Feb 10:47	Share

Appendix 4D and Half Year Report
27 Feb 10:42	Share

CLINUVEL Investor Webinar
20 Feb 09:05	Share

Change in substantial holding
17 Feb 08:20	Share

Preliminary results from SCENESSE adolescent EPP study
10 Feb 09:05	Share

Vitiligo - CUV105 Study Update
20 Jan 09:39	Share

SCENESSE Argentinian distribution agreement
17 Jan 09:22	Share

Managing Director Letter to Shareholders
23 Dec 09:18	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $9.83		Change -0.350(3.44%)		Mkt cap ! $492.7M

Open	High	Low	Value	Volume
$10.18	$10.18	$9.75	$1.391M	140.2K

Buyers (Bids)

No.	Vol.	Price($)
1	9965	$9.83

Sellers (Offers)

Price($)	Vol.	No.
$9.89	370	1

View Market Depth

No.	Vol.	Price($)
1	244	9.810
3	758	9.800
1	790	9.770
9	6875	9.750
3	221	9.700

Price($)	Vol.	No.
10.000	280	1
10.090	1000	1
10.200	1000	1
10.300	8649	2
10.400	1728	2

Last trade - 16.10pm 13/06/2025 (20 minute delay)

CUV (ASX) Chart

CLINUVEL PHARMACEUTICALS LIMITED

Latest Threads

Timeline

Featured News

Latest Articles

Clinuvel shares dip, even as CEO comes back from temp leave

After Clinuvel's (ASX:CUV) CEO Dr. Philippe Wolgen took time off back in March to respond to an "acute medical condition," it wasn't...

Clinuvel stroke drug shows 'positive' results – but some adverse effects left unclear

Clinuvel shares jumped on Tuesday on higher volumes as the company reported a clinical trial win with its stroke drug, 'PRENUMBRA.'

British study shows Clinuvel drug effective on DNA of UV-damaged skin

Clinuvel Pharmaceuticals Ltd has reported final results of its study of the efficacy of afamelanotide to repair the DNA of damaged skin.

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News